Clinical trials: Lung Non-Squamous Non-Small Cell Carcinoma
VEGFC Protein in Serum, VEGFC Protein in Non Small Cell Lung Cancer
Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma
Lung cancer and esophageal cancer remain the leading causes of cancer death worldwide. The main problem is lack of effective tool in early detection that accounts for the poor outcome of cancer.
- Conditions
- VEGFC Protein in Serum, VEGFC Protein in Non Small Cell Lung Cancer, VEGFC Protein in ESCC, CTTN Protein in ESCC
- Trial name
- NCT01240369
- Volunteers
- 250 people
- Sponsor
- China Medical University Hospital
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
This phase II trial studies how well nintedanib works in treating patients with advanced non-small cell lung cancer who have failed up to two previous chemotherapy regimens.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01948141
- Testing
- nintedanib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Imaging, Colorectal Cancer
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor…
- Conditions
- Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
- Trial name
- DUNP19 (NCT07272642)
- Testing
- LNTH-2403
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Radiopharm Theranostics, Ltd
Large Cell Lung Carcinoma, Lung Adenocarcinoma
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab (CPB) work when given with or without cixutumumab in treating patients with non-small cell lung cancer that is stage IV or has come back…
- Conditions
- Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT00955305
- Testing
- Bevacizumab, Carboplatin, Cixutumumab
- Where
- 165 sites in United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non-squamous NSCLC
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.
- Trial name
- NCT03768037
- Testing
- Anlotinib plus Pemetrexed, Pemetrexed
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-small Cell Lung Cancer Metastatic
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Primary Objectives: Study was designed with multiple primary endpoints analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS]) Study…
- Trial name
- CARMEN-LC03 (NCT04154956)
- Testing
- SAR408701, Docetaxel
- Where
- 169 sites in United States, Argentina and 24 more
- Volunteers
- 389 people
- Sponsor
- Sanofi
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in…
- Trial name
- NCT01496742
- Testing
- RO5490258, bevacizumab [Avastin], cisplatin/carboplatin
- Where
- 87 sites in United States, Argentina and 11 more
- Volunteers
- 259 people
- Sponsor
- Genentech, Inc.
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with…
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck
- Trial name
- NCT04504669
- Testing
- AZD8701, Durvalumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
- Trial name
- NCT05785741
- Testing
- DB-1310, Trastuzumab, Osimertinib
- Where
- 24 sites in United States, China
- Volunteers
- 1,000 people
- Sponsor
- DualityBio Inc.
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe…
- Conditions
- Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03916627
- Testing
- cemiplimab, Platinum Doublet, fianlimab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Regeneron Pharmaceuticals
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort…
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma
- Trial name
- TRAP (NCT02029690)
- Testing
- ADI-PEG 20
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Polaris Group
Lung Cancer
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280150
- Testing
- bevacizumab, carboplatin, erlotinib hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
- Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT05910827
- Testing
- HMBD-001, Docetaxel, Cetuximab
- Where
- 20 sites in Australia, Moldova and 3 more
- Volunteers
- 398 people
- Sponsor
- Hummingbird Bioscience
Carcinoma, Non-Small-Cell Lung, Secondary
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
This is an open-label, multicentre, randomized phase II trial. Eligible patients with Non Small Cell Lung Cancer (NSCLC) with high Thymidylate Synthase (TS) expression , will be randomly assigned with 1:1 ratio to the following…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Secondary, Advanced Stage IIIB, High Thymidylate Synthase Expression
- Trial name
- HighTySy (NCT02919462)
- Testing
- Oral vinorelbine, Cisplatin, Maintenance with Metronomic Oral Vinorelbine
- Where
- 5 sites in Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice
This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice.
- Trial name
- NCT01893268
- Where
- 88 sites in France
- Volunteers
- 279 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of karenitecin in treating patients who have relapsed or…
- Trial name
- NCT00010218
- Testing
- karenitecin
- Where
- 44 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Squamous Non Small Cell Lung Cancer
Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study
The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung…
- Trial name
- SAVE (NCT03646968)
- Testing
- Anlotinib and Docetaxel
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Yongchang Zhang
Non Small Cell Lung Cancer
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
A prospective ,multicenter ,non-interventional ,real-world study observing changes in molecular markers after three weeks of osimertinib targeted therapy in EGFRm NSCLC
- Trial name
- pre-FLAME (NCT06422546)
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Beijing Cancer Prevention & Treatment Society
Non-squamous Non-small Cell Lung Cancer
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
Chemotherapy is still the standard first-line treatment option for EGFR unmutated patients. After a randomized phase Ⅲ trial, BEYOND was presented the synergistic effect of progression-free survival(PFS) could be expected when…
- Trial name
- NCT03671538
- Testing
- Anlotinib, pemetrexed, Cisplatin
- Volunteers
- 62 people
- Sponsor
- Lingyu Luo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.